Genetically Modified Hepatitis B Surface Antigen: A Powerful Vaccine Technology for the Delivery of Disease-Associated Foreign Antigens

Author(s): Scott Thomson, Oscar Haigh, Allan Gould, Robert Tindle.

Journal Name: Current Drug Therapy

Volume 3 , Issue 3 , 2008

Become EABM
Become Reviewer


The surface antigen of hepatitis B virus (HBsAg) spontaneously aggregates into ‘empty’ virus-like particles (VLPs) in the absence of other viral components. The powerful immunogenicity of HBsAg when administered either as VLPs or as naked DNA invites its exploitation as a vector for the delivery of antigenic determinants from other organisms. Here we discuss ways in which HBsAg may be modified to derive vaccines against disease-related pathogens. We review studies demonstrating the induction of disease-protective antibody and T-cell responses induced by immunization with recombinant HBsAg vaccines, and consider how these vaccines might best be delivered. Unmodified HBsAg VLPs are licensed for use in humans as the pan-global vaccine to prevent hepatitis B virus infection, suggesting that route-tomarket for recombinant HBsAg vaccines might be simplified.

Keywords: Hepatitis B surface antigen, vaccine, DNA, virus-like particle, cytotoxic T-cell, antibody

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2008
Page: [226 - 234]
Pages: 9
DOI: 10.2174/157488508785747844
Price: $65

Article Metrics

PDF: 2